SecBot SecBot

VIR

Vir Biotechnology, Inc.
Nasdaq· Biological Products, (No Diagnostic Substances)· Inc. DE· CIK 0001706431 Biotech & Drug Discovery
$9.58 −0.38 (−3.82%)
Nov 16 4:00 PM ET · prev $9.96
Market cap
$2.1B
Mid cap
Consensus
Buy
92% Buy or better · 13 analysts
Median target
$23.00
+140% · range $17.00–30.00
1 year
+74.5%
from $5.49 · Nov 17
30 days
−6.2%
from $10.21
52-week range
$5.44–13.65
−30% from high · low Nov 19
Avg volume 20D
2.94M
Nov 13 spike 16.66M
Short interest
16.87M
≈9.8% of shares · +3.9%
Days to cover
11.9
at average volume
Insider net
−$2.4M
0 buyers · 7 sellers · since Feb 22
New fund stakes
0
Q3 2026 13F · 0 exits
Filing reports
36
analyzed by SecBot
SecBot read MIXED 18 reports · 90 days
Balance 4 bearish · 2 bullish · 12 neutral oldest → newest, height = score
Avg score ·High conf. 16/18

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InsidersBEARISH

    7 insiders sold $2.4M.

  • InstitutionsBEARISH

    Q3 2026: 9 added (0 new), 21 trimmed or exited.

  • AnalystsBULLISH

    12 of 13 rate it Buy or better. Every target is above the price.

  • EstimatesRISING

    Current-quarter EPS estimate −$0.647 → −$0.063 over 90 days. 2 up, 0 down in 30 days.

  • Short sellersSTEADY

    Short interest +3.9% to 16.87M shares. 11.9 days to cover, ≈9.8% of shares.

  • TrendRANGE

    14% below its 50-day average.

Who's buying

13F· Q3 2026
0
new positions
0
exits
FundMoveSharesValue
FMR LLCTRIM640,200$7.2M
RENAISSANCE TECHNOLOGIES LLCTRIM395,964$4.4M
Ensign Peak Advisors, IncTRIM390,021$4.4M
UBS Group AGTRIM253,980$2.8M
SEI INVESTMENTS COADD162,700$1.8M
Russell Investments Group, Ltd.ADD136,146$1.5M
VANGUARD ASSET MANAGEMENT, LtdADD101,402$1.1M
Jump Financial, LLCNEAR_EXIT86,988$972.5K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

13 analysts
Buy 92% rate it Buy or better
Strong Buy4Buy8Hold1Sell0Strong Sell0
12-month targets · 8 analysts

Price is below the lowest target. Median implies +140%.Targets as of Nov 17, 2026.

Recent actions
DateFirmActionRating
Nov 10, 2026Morgan Stanley
MAINTAIN
MAINTAINOverweight
Nov 10, 2026Evercore ISI Group
MAINTAIN
MAINTAINOutperform
Nov 9, 2026HC Wainwright & Co.
REITERATE
REITERATEBuy
Nov 9, 2026Needham
MAINTAIN
MAINTAINBuy
Nov 5, 2026Needham
MAINTAIN
MAINTAINBuy
Oct 7, 2026HC Wainwright & Co.
MAINTAIN
MAINTAINBuy

Insider ledger

Form 4
$0
bought · 0 insiders
$2.4M
sold · 7 insiders
DateInsiderTypeValue
Nov 15, 2026🔒 Fresh data, subscribers only
Nov 15, 2026
AWARD
Nov 15, 2026🔒 Fresh data, subscribers only
Nov 15, 2026
AWARD
Nov 15, 2026🔒 Fresh data, subscribers only
Nov 15, 2026
AWARD
Nov 3, 2026
de Verneuil Vanina
EVP, General Counsel, Corp Sec
Nov 3, 2026
SELL$26.7K
Nov 2, 2026
de Verneuil Vanina
EVP, General Counsel, Corp Sec
Nov 2, 2026
SELL$15.2K
Oct 27, 2026
Topalian Suzanne Louise
Director
Oct 27, 2026
AWARD9,462 sh
Oct 27, 2026
Topalian Suzanne Louise
Director
Oct 27, 2026
AWARD16,000 sh
Oct 27, 2026
Topalian Suzanne Louise
Director
Oct 27, 2026
AWARD4,731 sh

Earnings setup

Estimates
−$0.06
EPS estimate, this quarter
+90%
estimate change, 90 days
2↑ 0↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.06-$0.68–$0.77+90.0%$87.4M
Next Q-$0.44-$0.66–-$0.31-3.9%$17.0M
Current FY🔒 Fresh data, subscribers only
Next FY🔒 Fresh data, subscribers only

Washington

Corporate Lobbying

8 lobbying filings and 0 bills this company lobbies on, with spend, stage and how each bill touches it, are for subscribers.

Subscribe for Full Access

Short side

FINRA· Oct 30, 2026
16,874,443
shares short
+3.9%
vs prior settlement
11.9
days to cover
≈9.8%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Nov 16, 2026 SEC
🔒 Fresh report (last 24h), subscribers only
Nov 15, 2026 Insider
🔒 Fresh data, subscribers only
Nov 15, 2026 Insider
🔒 Fresh data, subscribers only
Nov 15, 2026 Insider
🔒 Fresh data, subscribers only
Nov 13, 2026 SEC
Vir Biotechnology priced an underwritten public offering of 15,000,000 shares of common stock at $10.00 per share…
8-K · Impact 5/10
Nov 12, 2026 SEC
Vir Biotechnology filed a preliminary prospectus supplement for an underwritten public offering of common stock, with…
424B5 · Impact 5/10
Nov 4, 2026 Earnings result
VIR Q3 2026 Earnings: EPS $-0.57 (+25.2% vs est)
Sep 30, 2026 Inst.
FMR LLC · TRIM
640,200 shares ($7.2M)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
5 drugs tracked · Drug pipeline →
Recent

SecBot reports

36 filings · 3 bullish · 8 bearish · 25 neutral
All VIR filing & press-release reports (36)